New hope for blood disorder patients who fail standard treatment
NCT ID NCT04081220
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This phase 2 trial tests an experimental drug called IMG-7289 (an LSD1 inhibitor) in 9 adults with essential thrombocythemia, a rare blood disorder causing too many platelets. Participants take the drug daily by mouth, and researchers check if it can bring platelet counts back to normal by 24 weeks. The study is for people who cannot use or have not responded to the standard drug hydroxyurea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOCYTHEMIA, ESSENTIAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mays Cancer Center
San Antonio, Texas, 78229, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMG-7289 (LSD1 inhibitor)
What this could lead to
If successful, this could offer a new treatment option for people with essential thrombocythemia who cannot tolerate or do not respond to current therapies.
What could go wrong
This is a very small early-phase trial with only 9 participants, so results may not apply broadly. The drug may not work or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.